Sustained virologic suppression with abacavir, emtricitabine, and crushed dolutegravir and tenofovir alafenamide in a patient with HIV and eosinophilic esophagitis

Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure

(2018) Marieke Roskam-Kwint et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression

(2018) Aleš Chrdle et al.   INTERNATIONAL JOURNAL OF STD & AIDS

Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration

(2017) Kristina M. Brooks et al.   PHARMACOTHERAPY

Virological suppression after use of crushed tenofovir-emtricitabine and dolutegravir tablets in a patient with HIV infection

(2016) L. Buscemi   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

A HAART-Breaking Review of Alternative Antiretroviral Administration: Practical Considerations with Crushing and Enteral Tube Scenarios

(2016) Emily Huesgen et al.   PHARMACOTHERAPY

Eosinophilic Esophagitis

(2015) Glenn T. Furuta et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Food on the Pharmacokinetics of the Integrase Inhibitor Dolutegravir

(2011) Ivy Song et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Role of Therapeutic Drug Monitoring in the Management of Patients With Human Immunodeficiency Virus Infection

(2011) Erina Pretorius et al.   THERAPEUTIC DRUG MONITORING

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

(2009) Caroline Bazzoli et al.   CLINICAL PHARMACOKINETICS